Research Driven
Strategic Investment
Global Collaboration
Healthcare Advancement
Supporting Innovation-Driven Companies Advancing the Future of Healthcare.
ARN Management participates in companies that demonstrate strong potential to contribute to scientific advancement and long-term industry innovation. Our investment approach focuses on organizations driven by research, technological progress, and meaningful impact in their respective fields.
Gelmedix represents one such company, operating at the intersection of biotechnology, therapeutic research, and biomedical innovation. Through continued scientific exploration and collaboration with industry partners, the company contributes to the broader ecosystem working toward improved healthcare solutions.
Our involvement reflects a long-term perspective centered on supporting organizations that pursue innovation responsibly while expanding the possibilities of modern medicine.
Regenerative Therapies for Vision Restoration
GelMEDIX is developing regenerative therapies designed to restore vision by regenerating damaged retinal cells. The company’s technology is built around a proprietary injectable hydrogel scaffold platform engineered to improve the delivery, safety, and integration of therapeutic cells and gene therapies.
The platform is designed to mimic natural tissue structures, supporting cell survival and integration while promoting tissue regeneration in targeted treatment areas.
$13M Seed Financing to Advance Lead Therapy Program
GelMEDIX recently completed a $13 million seed financing round with participation from multiple life sciences investors. The capital is being used to advance the company’s lead therapeutic program and continue development of its regenerative medicine technology platform.
The financing also supports ongoing research aimed at improving treatment approaches for patients suffering from advanced retinal diseases.
Industry Partnership Supporting Therapeutic Development
Alongside the financing milestone, GelMEDIX also announced its first strategic collaboration with a global pharmaceutical company. The partnership will utilize the company’s hydrogel scaffold technology to support the development of stem cell–derived therapies.
Such collaborations highlight growing industry interest in regenerative medicine platforms capable of advancing next-generation therapeutic solutions.
Partnering with Innovation-Led Companies to Support Long-Term Growth.
Strategic Investment
We invest in companies advancing breakthrough technologies and research-driven innovation with long-term global impact.
Long-Term Partnerships
Our philosophy focuses on patient capital, strategic alignment, and sustainable company growth.
Innovation Focus
We prioritize ventures built on deep technology, scientific discovery, and transformative ideas.
Global Network
Our ecosystem connects founders, researchers, and industry partners to accelerate innovation and growth.